116 results
8-K
EX-99.1
CKPT
Checkpoint Therapeutics Inc
24 Jun 24
Checkpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA Resubmission
7:46am
Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding our reaching alignment with the FDA on our cosibelimab
8-K
EX-10.1
CKPT
Checkpoint Therapeutics Inc
14 May 24
Departure of Directors or Certain Officers
7:30am
but without limitation the following: (a) asset write-downs or impairment charges; (b) litigation or claim judgments or settlements; (c) the effect
8-K
EX-99.1
CKPT
Checkpoint Therapeutics Inc
10 May 24
Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Updates
8:45am
statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act
8-K
EX-99.1
mch r75x0
22 Mar 24
Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
8:52am
8-K
EX-99.1
extejk
18 Mar 24
Checkpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of Directors
4:05pm
424B5
k1vsh9gdzrizdy97sh
30 Jan 24
Prospectus supplement for primary offering
5:10pm
8-K
EX-99.1
u7mnxte fb
30 Jan 24
Checkpoint Therapeutics Announces $14 Million Registered Direct Offering Priced At-the-Market
5:00pm
8-K
EX-10.1
a1k228 9pen207
30 Jan 24
Checkpoint Therapeutics Announces $14 Million Registered Direct Offering Priced At-the-Market
5:00pm
8-K
EX-99.1
7y12 gvsmy9
18 Dec 23
U.S. Food and Drug Administration Issues Complete Response Letter for Cosibelimab Solely Due to Inspection Findings at Third-Party Manufacturer
7:10am
8-K
EX-99.1
yqnn8ymbujfvh0 gaw
13 Nov 23
Checkpoint Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
5:10pm
8-K
EX-99.1
6s4azcd n1
3 Oct 23
Checkpoint Therapeutics Announces Exercise of Warrants for $11.13 Million in Gross Proceeds
5:00pm
8-K
EX-99.1
drlln8 28
14 Aug 23
Checkpoint Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
4:30pm